Investment analysts at Barclays PLC began coverage on shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) in a research note issued on Wednesday, MarketBeat.com reports. The brokerage set an “overweight” rating and a $104.00 price target on the biotechnology company’s stock. Barclays PLC’s target price would indicate a potential upside of 26.49% from the stock’s current price.

Several other brokerages also recently issued reports on ONCE. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Spark Therapeutics in a research report on Friday, August 25th. BidaskClub raised shares of Spark Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, August 26th. UBS AG reaffirmed a “buy” rating and issued a $92.00 price objective (up previously from $70.00) on shares of Spark Therapeutics in a research report on Thursday, August 3rd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $89.00 price objective (up previously from $69.00) on shares of Spark Therapeutics in a research report on Thursday, August 3rd. Finally, Evercore ISI began coverage on shares of Spark Therapeutics in a research report on Wednesday, August 16th. They issued an “in-line” rating and a $83.00 price objective for the company. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $83.77.

Shares of Spark Therapeutics (NASDAQ:ONCE) traded down 3.73% on Wednesday, hitting $82.22. 455,461 shares of the company were exchanged. The company has a 50-day moving average price of $77.32 and a 200 day moving average price of $62.21. Spark Therapeutics has a 52-week low of $35.07 and a 52-week high of $86.86. The firm’s market cap is $2.57 billion.

Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.75) by $0.14. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The business had revenue of $1.48 million for the quarter, compared to analyst estimates of $1.33 million. During the same period last year, the company posted ($1.04) EPS. The firm’s revenue for the quarter was up 14.7% compared to the same quarter last year. Analysts predict that Spark Therapeutics will post ($7.69) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Spark Therapeutics, Inc. (ONCE) Research Coverage Started at Barclays PLC” was first posted by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/09/10/spark-therapeutics-inc-once-research-coverage-started-at-barclays-plc.html.

In other news, CFO Stephen W. Webster sold 7,663 shares of the firm’s stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $60.00, for a total transaction of $459,780.00. Following the completion of the sale, the chief financial officer now owns 10,163 shares of the company’s stock, valued at $609,780. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Anand Mehra sold 211,858 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $70.15, for a total transaction of $14,861,838.70. The disclosure for this sale can be found here. Insiders have sold 371,160 shares of company stock valued at $26,468,351 in the last three months. Corporate insiders own 7.30% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in ONCE. Teachers Advisors LLC lifted its stake in Spark Therapeutics by 16.8% during the fourth quarter. Teachers Advisors LLC now owns 33,884 shares of the biotechnology company’s stock worth $1,691,000 after purchasing an additional 4,875 shares during the last quarter. Nationwide Fund Advisors lifted its stake in Spark Therapeutics by 2.5% during the first quarter. Nationwide Fund Advisors now owns 17,298 shares of the biotechnology company’s stock worth $923,000 after purchasing an additional 414 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Spark Therapeutics by 131.8% during the first quarter. Wells Fargo & Company MN now owns 522,894 shares of the biotechnology company’s stock worth $27,891,000 after purchasing an additional 297,277 shares during the last quarter. American Century Companies Inc. lifted its stake in Spark Therapeutics by 0.7% during the first quarter. American Century Companies Inc. now owns 488,519 shares of the biotechnology company’s stock worth $26,058,000 after purchasing an additional 3,445 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Spark Therapeutics by 10.9% during the first quarter. Bank of New York Mellon Corp now owns 111,043 shares of the biotechnology company’s stock worth $5,923,000 after purchasing an additional 10,916 shares during the last quarter. Hedge funds and other institutional investors own 91.01% of the company’s stock.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.